3^rd International Conference on Clinical Pharmacy December 07-09, 2015 Atlanta, USA

ROSEANE SANTOS, graduated at Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, as Pharmacist and as Biochemical-Pharmacist, a 5-year program. Before coming to United States, she worked as Hospital Pharmacist at the Federal University of Rio de Janeiro where she had the opportunity to be involved with different aspects of clinical research and drug monitoring. Her passage by the food and drug regulatory agency of Brazil, Division of Medicines (DIMED) and as consultant for Pharmaceutical Industry strengthened her skills on regulatory affairs. She also obtained her Master Degree in Hospital Pharmacy and accepted the position as Assistant Professor of Pharmacology at private and federal universities. In 1999, she was awarded a 4-year scholarship from Brazilian Government to study abroad and came with her family to USA for PhD. Program at State University of New York at Buffalo, from where she graduated on November of 2004. Her thesis involved the knowledge of basic molecular biology techniques as cloning, immunoassays, and state-of-the-art technology such as micro-arrays, gene sequencing and real-time PCR, looking to the most different aspects of the gene expression of interferon-beta induced genes, whether playing a role in therapeutic response or as disease biomarkers. After graduation she was appointed as Assistant Professor at Pharmaceutical Sciences Department of Nova Southeastern University College of Pharmacy, Fort Lauderdale, FL. At the present, she is Assistant Professor at South University School of Pharmacy, teaching in the area of main expertise – pharmacology. Dr. Santos research laboratory is focused in the area of Coffee and Health and her major interest is on recently discovered bioactive compounds present in coffee known as chlorogenic acids and lactones and their effects on human health. Her research focus is into the characterization of a biomarker for coffee intake to provide the necessary bridge between clinical studies (epidemiologic) and basic science (molecular biology). It will make possible to correlate coffee consumption biomarker levels of specific target study population, as to potential health effects. She also works in the development of healthy byproducts from coffee, such as functional and fortified coffee and serves as consultant for coffee industry.

Major interest is on recently discovered bioactive compounds present in coffee known as chlorogenic acids and lactones and their effects on human health. Her research focus is into the characterization of a biomarker for coffee intake to provide the necessary bridge between clinical studies (epidemiologic) and basic science (molecular biology)

Roger Jelliffe MD, FCP, FAAPS, developed the first computer software for individualizing drug dosage regimens in 1967. He was the first to relate renal drug elimination to creatinine clearance. He developed the first method for estimating creatinine clearance when serum creatinine is changing. He founded the USC Laboratory of Applied Pharmacokinetics in 1973, and the USC*PACK and more recent MM-USCPACK clinical software for individualizing drug dosage regimens most precisely. His laboratory developed the Resource for Population Modeling at the San Diego Supercomputer Center, the nonparametric adaptive grid (NPAG) population modeling approach, and Multiple Model (MM) design of maximally precise dosage regimens. This is now the Bestdose clinical and Pmetrics research software. We have developed three new methods of Bayesian analysis for individual patients. This adds great capability and safety in managing unusual patients. He is author or co-author of 132 peer reviewed publications, has mentored over 100 visiting scientific scholars, 1 sabbatical scholar, 2 Master’s Students, 3 Ph.D candidates, and 3 mini-sabbaticals.

Dr. Jelliffe’s interest is now in nonlinear PK/PD population modeling of multiple interacting drug systems, optimally coordinated combination MM dosage regimens for patients, and in methods using the dose itself as an active partner to learn about the patient optimally while having to treat him/her at the same time.

Dr. Noreddin received his Ph.D. in pharmaceutical Sciences from the University of the Pacific, California and received research training as a visiting scholar at the Department of Medicine, Stanford University. He had postdoctoral fellowship (Pharmacokinetics and Pharmacodynamics of Antimicrobials), Department of Medical Microbiology, University of Manitoba followed by an American College of Clinical Pharmacy postdoctoral fellowship (Infectious Diseases). Dr. Noreddin’s research interest includes Pharmacoklinetic/Pharmacodynamic modeling of anti-infective and anti-cancer therapy, clinical simulation and Monte Carlo analysis and bacterial resistance in biofilm studies. Dr. Noreddin has outstanding records of scientific and academic accomplishments with multiple research funding, numerous publications in highly prestigious journals and various presentations in both national and international conferences. He served as a scientific reviewer for the NIH as well as other national and international research institutions.

1. Pharmacokinetic/Pharmacodynamic modeling of anti-infective and anti-cancer therapy 2. Clinical simulation and Monte Carlo analysis 3. Bacterial resistance in biofilm studies 4. Cancer epigenetic studies

Stig Larsen has completed his DSc in Clinical Research Methodology at Ullevål Hospital, Oslo University Norway. He is professor at the Norwegian University of Life Science and has published more than 300 papers in international medicine and clinical research methodological journals.

Endoscopy
Gastrointestinal Diseases
Pancreatic Diseases

-Professor of Molecular Biology and Biochemical Pharmacology at the Faculty of Pharmaceutical Sciences, University of Lorraine (Emeritus) -Director of the postgraduate course in Biochemical Pharmacology (1977-2003) -Founder and member of Directing Group of DU “Thérapie Personnalisée – Pharmacogénétique” (2009-2011) -Member of the Board of the International Society of Pharmacogenomics (ISP) -Editor in Chief of Drug Metabolism and Drug Interactions -Past Editor in Chief of Clinical Chemistry and Laboratory Medicine (1997-2009) -Member of the Editorial Boards of : -Fundamental and Clinical Pharmacology -Pharmacogenomics -Personalized Medicine -Pharmacogenomics and Personalized Medicine: Advance and Applications -Current Pharmacogenomics and Personalized Medicine -International Journal of Clinical Pharmacology and Toxicology (IJCPT) -President of the European Society of Pharmacogenomics and Theranostics (ESPT) -Past-President of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) (1990-1996) -Chairman of the Expert Panel of the International Federation of Clinical Chemistry "Drug Effect in Clinical Chemistry"(1978-1986) -Member of the Council of the International Society for the Study of Xenobiotics (ISSX) (1982-1983) -Member of the Membership Affairs Committee of ISSX (1988-2002) -Chairman of the European Society of Biochemical Pharmacology (1984-1986) -Doctor Honoris Causa from Laval and Krakow Universities; member of the Royal Academy of Medicine in Belgium; and recipient of 27 awards from 16 different countries -Organizer of the Pont-à-Mousson Biologie Prospective Meetings (1970-2006) and the Santorini Biologie Prospective Colloquia (2002, 2004, 2006, 2008, 2010, 2012, 2014) -Author of more than 600 publications in peer reviewed journals

- Apo E isoforms and function - Pharmacogenomics and drug metabolizing enzymes and transporters - Cardiovascular biomarkers and systems biology for personalized health for cardiovascular drugs (Clopidogrel) - Proteomic biomarkers and reference values

Kazuo Nakamura has completed his Ph.D at the age of 37 years from Kagoshima University and postdoctoral studies from Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University. He is the professor of Nihon Pharmaceutical University. He has published more than 25 papers in reputed journals and serving as a councilor of The Japanese Pharmacological Society.

Prescription construction and analysis, Nutrition and Immunity, Clinical Pharmacology, Pharmaceutical Science,

Dr. Yousef Alomi, Head of General Administration of Pharmaceutical Care Administration, and Head of National Drug Information Center, MOH Saudi Arabia Dr. Alomi is a product of King Saud University confirmed with the degree of Bachelor of Pharmaceutical Sciences in the year 1992. After six-years of higher study, he earned his Master of Clinical Pharmacy from the same university in the 1998. He is an affiliated clinical instructor of Purdue University in the USA. He is adjunct assistant professor of King Saud University college of Pharmacy. Dr. Alomi worked as clinical pharmacist in critical care area and nutrition support. He is He is establish and implement several programs at MOH Hospitals at first time; Clinical Pharmacy Program, Medication Safety Program, Pain Management Program, Anticoagulation Program and Pharmacy Infection Control, including 30 Adult and 20 Pediatrics Clinical Pharmacy Program; he founder of Mass Gathering Pharmaceutical Care in Saudi Arabia. He became a member of advisory board of the Arab Pharmaceutical Journal in 2010. He became as Pharmacy Board Member of Saudi Commission of Health Care Specialities2010-2013. He had several research papers in clinical Pharmacy and Pharmacy practice published in ACCP and ISPOR conferences; He had several presentations in the clinical pharmacy and pharmacy practice at several conferences in and outside Saudi Arabia.

clinical pharmacy, pharmacy practice

Stefan Bughi, MD, MACM, FABD- Clinical Associate Professor of Medicine at the Keck School of Medicine, University of Southern California in Los Angeles, in the Division of Diabetes/Endocrinology. He has been a USC faculty since 1990 and since then he has been teaching USC and Western University 3rd and 4th year medical students, and house staff who had Diabetes/Endocrine rotation at Rancho Los Amigos National Rehabilitation Center (RLANRC. He is Board Certified in Internal Medicine and Endocrinology and Metabolism, and he is working as Physician Specialist at Rancho Los Amigos National Rehabilitation Center (RLANRC). At RLANRC, currently he is the Physician Patient Safety Officer, the Chair of Graduate Medical Education and the Chair of the Physician Well-Being Committee. He is a Fellow of the American Board of Diabetes and Fellow of the American Institute of Stress. He also has graduated from the USC Learning and Leadership Fellowships, and completed the Master in Academic Medicine at USC Keck School of Medicine. His research interests include the endocrinology of stress and the effects of stress on psychosomatic disorders. Presently he is conducting research on stress and medical profession, and give lectures on stress management to health care professionals. He also conducts research related to patient safety and medication errors, including studies on diabetes and hypoglycemia.

Effects of hynotherapy on peripheral and cardiac neurotransmitters
Coronary vasomotor tone in patients with microvascular angina

Céline Moch has completed his PhD at the age of 30 years from University Claude Bernard of Lyon (France). He is hospital pharmacist at Hospices Civils de Lyon. She has published around 10 papers in reputed journals.

Pharmacology
Pharmacy
Clinical Pharmacology